Clinical Trial Protocol Synopsisv0.1.2

A principal investigator at an academic cancer center needs to convert an investigator concept for a Phase 1 first-in-human trial into a draft ICH M11 CeSHaRP-aligned synopsis. The skill guides intake on indication, nonclinical NOAEL, starting-dose rationale, PICOT population, and estimand attributes, while flagging unknowns for sponsor medical and safety committee review. Output is a DRAFT synopsis with open-questions list ready for IRB and biostatistics review.

A sponsor medical writer with a target product profile and prior Phase 2 data must produce a Phase 3 protocol synopsis aligned to ICH E6(R3), ICH M11, and ICH E9(R1) estimands for FDA, EMA, and PMDA submission planning. The skill collects target regions, comparator justification, statistical considerations, and estimand attributes one question at a time, then returns a jurisdiction-tagged DRAFT synopsis. Regulatory, biostatistics, and pharmacovigilance reviewers finalize it before any IND/CTA filing.

A clinical-operations lead at a medical device start-up needs a pivotal device study synopsis following the ICH M11 template but tailored to FDA IDE requirements. The skill elicits device tier, intended use, comparator (sham/standard of care), endpoint definitions, and estimand construction, then produces a draft synopsis with assumptions and open questions. The team uses it as the starting point for pre-submission and IRB review.

A CRO clinical research associate supports a sponsor-investigator preparing an investigator-initiated Phase 2 study in a rare disease. The skill helps structure eligibility criteria, rescue therapy rules, special population handling (pediatric or hepatic impairment), and exploratory biomarker objectives into a jurisdiction-neutral draft synopsis. Unknown literature values are logged for verification, and the output is clearly marked as requiring sponsor medical, biostatistics, and IRB review.

A regulatory lead for a marketed product needs a post-market (Phase 4) protocol synopsis to evaluate a real-world safety signal under EMA and Health Canada requirements. The skill structures the PICOT, estimand table, sample-size assumptions, and special-population exclusions, referencing the SmPC/label for dose and indication. The draft synopsis is prepared for sponsor safety committee and ethics review, with every assumption explicitly named.

Annual subscription or seat-based licensing for sponsor medical writing, regulatory, and clinical operations teams who need to accelerate protocol synopsis drafting while maintaining ICH compliance. The skill integrates with document management and eTMF systems and is customized for sponsor SOPs and template libraries.

OEM or API integration where the skill is packaged as a feature inside CTMS, eClinical, or regulatory publishing platforms. The platform vendor sells it as an add-on to sponsors and academic research organizations, with the skill handling intake and draft generation while the platform manages document lifecycle.

Discounted subscription for academic medical centers, cooperative groups, and nonprofit research organizations that conduct investigator-initiated trials. The offer includes protocol synopsis drafting assistance, training on ICH M11 and estimand construction, and a shared template repository.